Piramal Pharma Limited gibt Ergebnisse für das 2. Quartal und das 1. Halbjahr des Geschäftsjahres 2027 bekannt

Piramal Pharma reported Q2 FY27 revenue of ₹2,617 crore, up 28% year over year, and EBITDA of ₹385 crore, up 72%; the EBITDA margin improved to 14.7% from 11.0%. H1 FY27 revenue rose 23% to ₹4,887 crore and EBITDA increased 72% to ₹669 crore, while the company posted a ₹64 crore net loss versus a ₹181 crore loss a year earlier. After the strong first half, Piramal raised its FY27 revenue-growth outlook to 19–20% and expects significantly higher profitability.

Analysis

The key read-through is operating leverage, not simply top-line acceleration: margin expansion suggests improved asset utilization, but it needs to persist as new capacity and customer programs scale. The quality-of-earnings check is less comfortable: EBITDA gains have not yet translated into positive net income, while higher depreciation and a ₹695 crore increase in net debt since March leave less room for execution slippage. Rising intangible assets and CWIP also make cash conversion and returns on investment important diligence points.

Over the next 1–3 months, the raised FY27 outlook and strong CDMO activity can support sentiment, but the next catalyst is management’s call commentary on conversion of customer wins/audits into revenue, utilization, and cash generation—not the activity counts themselves. Over 6–18 months, sustained CDMO demand could improve fixed-cost absorption; conversely, delayed programs, pricing pressure, or quality/regulatory setbacks could reverse utilization gains while depreciation and financing costs remain. The H1 growth rate already exceeds the new full-year growth range, so the guidance implies a slower H2 pace than H1; that may be prudent rather than a warning, but warrants scrutiny.

AbbVie’s associate/JV is mentioned without quantified contribution or evidence of a material change to AbbVie economics; this is not an ABBV catalyst. The contrarian risk is treating one strong half-year as a durable margin reset before profits and free cash flow validate it.

Key Decisions for Investors

• Piramal Pharma: no immediate chase; consider a small, conditional long only if the earnings call confirms CDMO program conversion, sustained utilization-led margins, and improving cash conversion. Reassess on the next results.
• Set a 1–3 month watch item for net debt, operating cash flow, and capex/CWIP. Falsify the margin-recovery thesis if EBITDA margin retreats materially or debt continues rising without corresponding cash generation.
• Do not trade ABBV on this release: the article provides no quantified earnings or outlook impact for AbbVie. Revisit only if the associate/JV contribution or a material commercial linkage is disclosed.